The Future Of Automation In CGT: Interview With Andreas Knaack

As cell and gene therapies move toward serving larger patient populations, manufacturing systems must evolve with them. Invetech CEO Andreas Knaack examines how automation can improve consistency, protect critical biology, and reduce waste during scale-up. He explains why many technologies developed for early-stage laboratory work are not designed for commercial volumes, making current robotic solutions an important bridge rather than a complete long-term answer. Looking ahead, the industry will need equipment that can support development through high-volume manufacturing without adding prohibitive costs. Achieving that goal will also require closer collaboration among scientists, technology providers, and industry partners.

Hear how lean principles, purpose-built tools, and strategic partnerships can help create safer, more efficient, and scalable manufacturing processes for cell and gene therapies.